BIA Monitoring and Exercise for the Prevention of Muscle Loss With Incretin Therapy (BICEP Study)

What this Trial Is About

Researchers are studying whether using a smartwatch that tracks activity levels and body composition, along with exercise reminders, can safely help improve strength and muscle mass in people who have recently started or plan to start treatment with incretin therapy medications called GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide, or retatrutide). These medications are used to manage conditions such as obesity and body composition changes. Participants will be randomly assigned to one of two groups. One group will receive a smartwatch to monitor their exercise and body composition, with exercise goals set and reminders provided on the device. The other group will receive general guidance on recommended exercise without the smartwatch. This study does not use blinding and follows participants over six months. During the study, participants will have their lean mass and other body composition measures checked at six months. Assessments will include hand grip strength, physical performance tests like the 1-minute sit-to-stand and 6-minute walk test, and physical activity scores. Researchers will monitor these outcomes to evaluate changes in muscle and fat mass and overall physical function throughout the study period.

Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment